Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
41055698 (PubMed )
Supplement: BLOOD_BLD-2024-027009-mmc4.xlsx › Sheet_1
Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.
Mallen JJ et al.
Journal of Biomolecular Structure & Dynamics, 2025
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K et al.
International Journal of Molecular Sciences, 2024
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA et al.
Blood Advances, 2023
37257190 (PubMed )
Supplement: BLOODA_ADV-2022-009366-mmc1.pdf
Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS et al.
Blood Advances, 2023
36269842 (PubMed )
Supplement: BLOODA_ADV-2022-008121-mmc1.pdf
Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.
Elamin G et al.
Journal of Molecular Modeling, 2022
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Estupiñán HY et al.
Leukemia, 2021
KinaseMD: kinase mutations and drug response database.
Hu R et al.
Nucleic Acids Research, 2021
33137204 (PubMed )
Supplement: gkaa945_supplemental_files.zip › Supplementary_Table_S3.xlsx › Sheet1
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacological Research, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR et al.
Acs Chemical Biology, 2016
Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: Report from Shanghai, China (2000-2015).
Chen XF et al.
Medicine, 2016
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ et al.
Jama Oncology, 2015
Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.
Lee PP et al.
Journal of Clinical Immunology, 2010
Select a paper to view details